BEIJING, Dec 30 (Reuters) - Shanghai Fosun Pharmaceutical
Group will set up a joint venture with
Germany's BioNTech to produce COVID-19 vaccines in
China, financial magazine Caixin reported on Wednesday.
The first phase of the China-based manufacturing facility
will have a production capacity of 200 million doses, Caixin
said, citing people familiar with the matter. It did not specify
how long it would take to produce that many doses.
A spokesman from Fosun declined to comment on the report.
Fosun Pharma had said it aims to move from importing
finished vaccine from the German firm to conducting some filling
procedures on its own, using imported bulk ingredients and then
eventually making vaccines from scratch, although it has not
announced a specific timeline.
Fosun said earlier this month it will buy at least 100
million doses of vaccine from BioNTech for use in mainland China
next year, if the vaccine receives regulatory approval in the
(Reporting by Roxanne Liu and Ryan Woo; Editing by Kim Coghill)